Thread by @AnooBhu, My interview with CCMB director, clarifies a big doubt we've had: "Nothing [...]

My interview with CCMB director, clarifies a big doubt we've had:

"Nothing Very Unusual About SARS-CoV-2 In India That Makes It More Or Less Virulent" https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/

'Nothing Very Unusual About SARS-CoV-2 In India That Makes It More Or Less Virulent' |

Indian scientists, like their global counterparts, are working to understand the SARS-CoV-2 virus and to sequence it with the hope of arriving at a drug or a vaccine for COVID-19. In this interview,

https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/

This responds to what gov scientists in Gujarat claimed, that there are diff strains and that high COVID19 mortality rates in Gujarat may be due to "more virulent strain" https://economictimes.indiatimes.com/news/politics-and-nation/wuhans-l-strain-may-be-behind-gujarats-high-death-rate-experts/articleshow/75390437.cms

Wuhan's L-strain may be behind Gujarat's high death rate: Experts

The dominance of the more virulent L-type coronavirus strain as compared to the S-type one could be behind the high mortality rate in the state, which has reported 133 deaths so far. However, no...

https://economictimes.indiatimes.com/news/politics-and-nation/wuhans-l-strain-may-be-behind-gujarats-high-death-rate-experts/articleshow/75390437.cms

3. CCMB is keen for private companies to come forward, take their research &run with it: "Companies can come forward ... We can license it at really negligible fees. As a government lab, we are not supposed to make money out of this but whatever technologies can go to public..."

4. Rakesh Mishra says CCMB is working w/ @Bioconlimited and @SyngeneIntl on.... "something really dramatic called ‘Next Generation Sequencing’. With this project, we will be able to test 10,000 or 20,000 samples in one go."

Idea came from @broadinstitute. https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/

'Nothing Very Unusual About SARS-CoV-2 In India That Makes It More Or Less Virulent' |

Indian scientists, like their global counterparts, are working to understand the SARS-CoV-2 virus and to sequence it with the hope of arriving at a drug or a vaccine for COVID-19. In this interview,

https://www.indiaspend.com/nothing-very-unusual-about-sars-cov-2-in-india-that-makes-it-more-or-less-virulent/

You can follow @AnooBhu.

Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: